• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a mask, and particularly to a mask that can inactivate viruses that adhere to it, even in the presence of lipids and proteins, irrespective of whether or not the viruses have an envelope. the mask can inactivate viruses by adhering to it and includes a mask body provided with a limb used when the mask is put on and the fine viral inactivation particles having a viral inactivation ability and maintained by the mask body. the viral inactivation fine particles are particles of at least one of the selected group of platinum(ll) iodide, palladium(ll) iodide, silver(i) iodide, copper(i) iodide, and copper(i) thiocyanate ).
    公开号:BR112012006914B1
    申请号:R112012006914-4
    申请日:2010-09-30
    公开日:2021-06-01
    发明作者:Yoshie Fujimori；Youhei Jikihara；Tetsuya Sato；Yoko Fukui；Tsuruo Nakayama
    申请人:Nbc Meshtec, Inc；
    IPC主号:
    专利说明:

    [0001] The present invention relates to a mask, and particularly a mask that can inactivate several viruses that adhere to it, even in the presence of lipids and proteins, regardless of whether or not the viruses have an envelope. State of the Art
    [0002] A few years ago, deaths were reported to be caused by infections with new types of viruses such as SARS (severe acute respiratory syndrome) and avian influenza. Currently, due to developments in virus transport and mutations, the world faces the risk of a "pandemic disease" that is an epidemic of viral infection throughout the world, and there is an urgent need for countermeasures. To deal with this situation, the development of vaccines based on antiviral drugs is accelerated. However, since vaccines have their own specificities, they can only prevent infections with specific viruses. Furthermore, preparing vaccines for the new types of virus requires a considerable amount of time.
    [0003] To avoid infections with such viruses, it is recommended to wear a mask. However, the problem with wearing a mask is that secondary infection can occur because viruses adhere to the mask used and can adhere to the hands when the mask is discarded. In this sense, a mask is of little use in preventing infection perfectly.
    [0004] To solve the above problem, masks having the effect of viral inactivation (reducing virus infectivity or virus inactivation) have been proposed (eg Patent Literatures 1 and 2). Patent Literature 1 proposed a mask having the effect of inactivating bacteria and viruses. More specifically, iodine is adsorbed onto anion exchange fibers prepared by binding ionic exchangeable functional groups such as amine groups to the fiber matrix, and a fabric containing the adsorbed iodine fibers used for the mask body. In a mask in Patent Literature 2, a fabric supporting a component extracted from SASA VEITCHII and a porous inorganic material is used for the body of the mask to impart the viral inactivation effect to the mask.Citation ListPatent LiteraturePatent Literature 1: Application Japanese Patent Application Disclosed No.2005-28230Patent Literature 2: Japanese Patent Application Disclosed No.2004-323430 Invention Summary Technical Problem
    [0005] Although Patent Literature 1 demonstrates that the mask has an effect on bacteria such as Escherichia coli, examples have not been given for viruses. In this sense, it is not known whether the mask has the effect of viral inactivation or not.
    [0006] In the example of Patent Literature 2, an antiviral test in the mask is demonstrated. However, the virus used in the test is an RS (Respiratory Syncytial) having an envelope. Viruses can be classified into those having no envelope such as noroviruses and those having an envelope such as influenza virus. Although a drug can inactivate viruses having an envelope, this drug should not be effective for viruses that do not have an envelope. In Patent Literature 2, none of the mask examples are described as non-enveloped viruses. In this sense, it is not known whether the mask has the same effect on the non-enveloped virus.
    [0007] A mask is an article used to cover the wearer's mouth and nose, and lipids and proteins contained in bodily fluids such as saliva can adhere to the mask. In this regard, it is preferable that the mask can inactivate viruses even in an environment where lipids and proteins are present. However, the mask in Patent Literature 2 is not tested in such an environment.
    [0008] To solve the aforementioned problems, the present invention provides a mask that can inactivate the adhesion of the virus to it, even in the presence of lipids and proteins regardless of whether or not the virus has an envelope. Solution to Problem
    [0009] A first aspect of the present invention provides a mask that can inactivate a virus that adheres to it, the mask characterized in that it comprises: a mask body provided with a limb used when the mask is worn; and viral inactivating fine particles having an ability to inactivate the virus held in the body of the mask, the viral inactivating fine particles being particles from at least one of the selected group consisting of platinum(II) iodide, palladium(II) iodide, silver(I) iodide, copper(I) iodide, and copper(I) thiocyanate.
    [00010] A second aspect of the invention is the mask according to the first aspect, characterized in that the fine particles of viral inactivation are attached to the mask body at least through a silane monomer and/or a polymerization product of the monomer of silane.
    [00011] A third aspect of the invention is the mask according to the first aspect, characterized in that the fine particles of viral inactivation are maintained in the mask body through groups of other fine inorganic particles that are attached to the mask body through chemical bonds with a silane monomer and/or a polymerization product of the silane monomer.
    [00012] A fourth aspect of the invention is the mask according to any of the first to the fourth third aspects, characterized in that the mask body includes a plurality of breathable filter members stacked in the thickness direction of the mask body, and particles viral inactivation thins are maintained by at least one of the plurality of filter members constituting the body of the mask.
    [00013] A fifth aspect of the invention and the mask according to the fourth aspect, characterized in that the fine particles of viral inactivation are maintained by at least one filter member that is located on the innermost side when the mask is worn.
    [00014] A sixth aspect of the invention is the mask according to the fourth and fifth aspects, characterized in that the viral inactivation particles are maintained by at least one filter member that is located on the outermost side when the mask is worn.
    [00015] A seventh aspect of the invention is the mask according to any of the first to sixth aspects, characterized in that the average diameter of the fine particles of viral inactivation is 1 nm or more or less than 500 nm.Advantageous Effects of the Invention
    [00016] According to the present invention, there is a mask that can easily inactivate various viruses such as a virus surrounded by a membrane referred to as an envelope containing a lipid and a virus having no envelope, and that can inactivate the virus independently in the presence of , in addition to the virus, the lipids and proteins resulting from, for example, the adhesion of droplets. Brief Description of Drawings
    Fig. 1 is a perspective view of a mask of a first configuration. Fig. 2 is a partially sectioned perspective view of the mask of the first configuration. Fig. 3 is a perspective view of a mask of another configuration. Fig. 4 is a perspective view of a mask from another configuration.
    [00017] A first configuration will now be described specifically with reference to Fig. 1.
    [00018] First, the general configuration of a mask 100 of the first configuration that can inactivate the virus will be described. The mask 100 of the first configuration includes a mask body 10 having a substantially rectangular shape and rubber cords 2 (corresponding to limbs used when the mask is donned) which are sewn at both ends of the longitudinal edges of the mask body 10 and are to be stretched around the ears.
    [00019] As shown in Fig. 2, in the first configuration, the mask body 10 includes a plurality of breathable filter members 1 (three in the first configuration), and the filter members 1 are stacked in the thickness direction of the body. mask 10 and integrated by welding. As shown in Fig. 1, several folds 4 (four in the first configuration) extending in the longitudinal direction are formed in the mask body 10 so that the mask body can freely change width according to the size of the wearer's face. folds 4 can open in the vertical direction so that three-dimensional spaces are formed in front of the nose and mouth. In this sense, the contact of the mask with the mouth and nose is loose. This makes breathing easier and reduces the amount of cosmetics that adhere to the mask. The integration processing described above is not limited to solder bonding, and any other method such as stitching can be used. In Fig. 2, in order to facilitate understanding, the folds 4 and the thread-like bands 3 described below are omitted from the figure. In Fig. 2, in order to facilitate understanding of the present application, the plurality of filter members 1 are shown. However, this is just an example, and filter member 1 can be composed of a single layer.
    [00020] Wire-shaped bands 3 made of a flexible metal or resin is inserted into the upper edge of the body of the mask 10. The formation of a flap between the mask 100 of the first configuration and the user's nose can be prevented by bending the wire-shaped bands 3 so that it extends along the contour of the user's nose. In this sense, problems such as fogging of the glasses by breathing and the intrusion of the virus along with the outside air through the flap can be solved.
    [00021] A description will be given below of the filter member 1 constituting the mask body 10. As described, in the first configuration, the three filter members 1 are stacked in the thickness direction of the mask body 10, The fine particles of viral inactivation having a viral inactivation capability are attached, at least through a silane monomer or an oligomer obtained by the polymerization of the silane monomer, to the outer surfaces of the filter members 1 which are located on the inner and outer sides in the direction of thickness, that is, they are located on the inner and outer sides when wearing the mask. No particular limitations are imposed on the dimensions of filter member 1, and a person skilled in the art can appropriately establish the dimensions. For example, the dimensions of filter member 1 for adults may be different from those for children. When filter member 1 is composed of a single layer, fine viral inactivation particles are attached to both sides of filter member 1.
    [00022] In the first configuration, viral inactivation fine particles are fine particles of at least one inorganic compound selected from the group consisting of platinum(II) iodide, palladium(II) iodide, silver(I) iodide, copper(I), and copper(I) thiocyanate and can inactivate viruses regardless of whether or not the virus has an envelope. In this regard, the mask 100 of the first configuration can be considered to hold an antiviral agent including fine particles of at least one inorganic compound selected from the group consisting of platinum(II) iodide, palladium(II) iodide, silver(I) iodide ), copper(I) iodide, and copper(I) thiocyanate. The fine viral inactivation particles of the first configuration can inactivate viruses even in the presence of proteins and lipids.
    [00023] At present, the viral inactivation mechanism of the fine particles of viral inactivation is unclear. The mechanism is adopted to be as follows. When the fine viral inactivation particles come into contact with the airborne mixture or droplets, some of the fine viral inactivation particles resist a reduction-oxidation reaction. This causes some effects on the electrical charge of the surface or membrane protein or DNA of the virus adhering to the mask 100 of the first configuration, and the viruses are thereby inactivated.
    [00024] No particular limitations are imposed on the size of the fine viral inactivation particles maintained, and a person skilled in the art can appropriately adapt size. However, the average particle diameter is preferably 1 nm or more and less than 500 nm. When the average particle diameter is less than 1 nm, the fine viral inactivation particles are physically unstable and agglutinate with each other. Therefore, it is difficult to fix the particles on the filter member 1 evenly. When a the mean particle diameter is 500 nm or more, the adhesion between the particles and filter member 1 is less than when the mean particle diameter falls within the above range. In the present description, the mean particle diameter is a volume of the mean particle diameter.
    [00025] In the first configuration, the fine viral inactivation particles are fixed on the filter member 1 through a binder. No particular limitations are imposed on the binder used. The molecular weights of the silane monomer or oligomer obtained by polymerizing the silane monomer are low. In this sense, these monomers and oligomers are preferred because the contact between the fine viral inactivation particles and viruses is less likely to be prevented, and viruses can be effectively inactivated. Furthermore, since the adhesion of the binder to the filter member 1 used as substrates is provided by the use of silane monomer and/or the oligomer as the binder, the fine viral inactivation particles can be more stable supported on the filter member 1.
    [00026] Specific examples of the silane monomer used for the mask 100 of the first configuration include silane monomers represented by a general formula X-Si(OR)n (n is an integer from 1 to 3). X is a functional group that reacts with an organic material, and examples thereof include a venera group, an epoxy group, a styryl group, a methacrylic group, an acryloxy group, an isocyanate group, a polysulfide group, an amine group, a mercapto group, and a chlorine group. Each OR is a hydrolyzable alkoxy group such as a methoxy group or an ethoxy group, and the three functional groups on the silane monomer can be the same or different. These alkoxy groups including methoxy and ethoxy groups are hydrolyzed to form silanol groups. The reactivity of such a silanol group, a vinyl group, an epoxy group, a styryl group, a methacrylic group, an acryloxy group, an isocyanate group, and functional groups having an unsaturated binder and the like is known to be high. More specifically, in the mask 100 of the first configuration, the fine viral inactivation particles are firmly held on the surface of the filter member 1 by chemical bonds through the silane monomer having high reactivity.
    [00027] Examples of the silane monomer represented by the general formula include vinyltrichlorosilane, vinyltrimethoxysilane, vinyltriethoxysilane, a vinyltriacetoxysilane, N-β-(N-vinylbenzylaminaethyl)-Y-aminopropyltrimethoxysilane, an N-(vinylbenzyl)-2-aminoethyl-3 hydrochloride -aminopropyltrimethoxysilane,3-glycidoxypropyltrimethoxysilane,3-glycidoxypropyltriethoxysilane,3-methacryloxypropylmethyldimethoxysilane, 3-methacryloxypropylmethyldiethoxysilane, 3-acryloxypropyltrimethoxysilane, bis(triethoxysilylpropyl)tetrasulfide, 3-aminopropyltriethoxysilane, 3-methacryloxypropylmethyldimethoxysilane, N-phenyl-3-aminopropyltrimethoxysilane, N-2-(aminoethyl)-3-aminopropylmethyldimethoxysilane, N-2-(aminoethyl)-3-aminopropyltrimethoxysilane, N-2-(aminoethyl)-3-aminopropyltriethoxysilane, 3-mercatpopropylmethyldimethoxysilane, 3- mercaptopropyltrimethoxysilane, N-phenyl-3-aminopropyltrimethoxysilane, special aminasilanes, 3-ureidopropyltriethoxysilane, 3-chloropropyltrimethoxysilane, tetramethoxysilane, tetraethoxy silane, methyltrimethoxysilane, methyltriethoxysilane, dimethyldiethoxysilane, phenyltriethoxysilane, hexamethyldisilazane, hexyltrimethoxysilane, decyltrimethoxysilane, hydrolyzable group containing siloxanes, fluoroalkyl group containing oligomers, methylhydrogensiloxane, and silicone quaternary ammonium salt.
    [00028] Examples of silane-based oligomers include commercially available oligomers KC-89S, KR-500, X-40-9225, KR-217, KR-9218, KR-213, and KR-510, which are all products from Shin-Etsu Chemical Co., Ltd. These silane-based oligomers can be used alone, as a mixture of two or more of the same, or as a mixture with one or two or more of the silane monomers described above.
    [00029] In the mask 100 of this configuration, one that the silane monomer or oligomer thereof exhibit sufficient bond strength even when only a small amount is used, the use of the silane monomer or oligomer thereof as a binder allows the exposed areas of the fixed virus inactivation fine particles to be enlarged. In this sense, the probability of contact of viruses adhering to the surface of mask 100 with the fine viral inactivation particles may be greater than when the fine viral inactivation particles are attached to filter member 1 using a binder such as a synthetic resin except the silane monomer or oligomer thereof. Viruses can thereby be effectively inactivated even by the use of a small amount of fine viral inactivation particles.
    [00030] Since the viral inactivation fine particles are firmly attached to filter member 1 by chemical bonds with silane monomer or oligomer thereof, the amount of viral inactivation fine particles falling from filter member 1 is significantly reduced by comparison as when the particles are covered and fixed with, for example, a general binding component. In this sense, the mask 100 of the present configuration can maintain its viral inactivation effects for a long period. The fine viral inactivation particles can be maintained by a condensation reaction, amide binders, hydrogen binders, ion binders, van der Waals forces, or physical adsorption. This can be achieved by selecting an appropriate silane monomer to be used.
    [00031] In the first configuration, no particular limitation is imposed on the form of fixation of the fine viral inactivation particles on the filter member, and the form can be appropriately selected by one skilled in the art. For example, the respective fine particles can be spread on the filter member 1. The inorganic fine particles can be maintained as inorganic fine particles aggregated two or three dimensionally.
    [00032] More specifically, the fine particles of viral inactivation can be kept, for example, in a spot, island, or in the form of a thin film. When the viral inactivation particles are maintained as three-dimensional aggregates, they include particles attached to the filter member 1 through the silane monomer or oligomer thereof (such particles are referred to as the viral inactivation fines a) and particles attached to the filter member. filter 1 through at least fine viral inactivation particles a.
    [00033] Preferably, the virus inactivating fine particles are kept in the filter member 1 as three-dimensional aggregates because a large number of fine irregularities are formed on the surface of the filter member 1 and the adhesion of dirt and the like to the mask body 10 is suppressed by the irregularities. The suppression of adhesion of dirt and the like allows the viral inactivation effect of the mask 100 to be maintained for a long period.
    [00034] In the mask 100 of the first configuration, an optionally used functional material, in addition to the fine viral inactivation particles, to impart a desired function to the mask 100 can be maintained on the surfaces of the filter member 1 constituting the mask body 10, Examples of functional material include other antiviral agents, antimicrobial agents, antifungal agents, antiallergenic agents, and catalysts. In this way, a functional material can be attached to the filter member 1, the fine viral inactivation particles, and the like by, for example, a binder. As with viral inactivation fine particles, the functional material can be bonded to the filter member 1 through chemical bonds between the silane monomer or oligomer bonded to the surface of the functional material and the surface of the filter.
    [00035] One skilled in the art can appropriately establish the amount of viral inactivation fine particles maintained in the mask 100 of the first configuration, in consideration of the purpose of mask use and application and the size of the fine particles. The amount of fine viral inactivation particles held in the mask body 10 is preferably 1.0 percent by mass to 80.0 percent by mass the sum total mass of substances held in filter member 1 constituting the mask body 10 and more preferably 5.0 percent by mass to 60.0 percent by mass. When the amount of fine viral inactivation particles is less than 1.0 percent by mass, the viral inactivation activity is less than when the amount falls within the above range. When the amount is greater than 80.0 percent by mass, the viral inactivation effect is not vastly different than when the amount falls within the above range. Furthermore, the binding properties of the oligomer formed by the silane monomer condensation reaction are reduced, and therefore the fine viral inactivation particles fall off from filter member 1 more easily than when the amount falls within the above range. In the present description, substances held in filter member 1 may include a silane monomer or oligomer thereof.
    [00036] A description will be given below of the filter member 1 keeping the fine particles from viral inactivation. In the first configuration, no particular limitations are imposed on the shape of the filter member 1, as long as it has breathability. Viral inactivation material can be held on surfaces in various shapes. Examples of filter member 1 include fabrics such as fabrics, knits, and nonwovens, and sheets of blended paper that are formed from materials, for example, various resins, synthetic fibers, natural fibers such as cotton, hemp, and silk, and Japanese paper obtained from natural fibers, which can be chemically joined to silane monomer in the fine viral inactivation particles on the surface of filter member 1. Specific examples of such materials of filter member 1 include polyester, polypropylene, polyethylene terephthalate, nylon, acrylic, polyacrylic acid, polymethyl methacrylate, artificial silk, acetate, triacetate, cotton, hemp, wool, silk and bamboo. A person skilled in the art can appropriately establish the shape of the filter member 1 according to the shape of the mask body 10,
    [00037] The manufacturing method of the mask 100 of the first configuration which has the fine particles of viral inactivation maintained thereafter will be described more specifically below.
    [00038] First, at least one is selected from platinum (II) iodide, palladium (II) iodide, copper (i) iodide, silver (I) iodide, and copper (I) thiocyanate, and the material selected is pulverized into particles of the order of sub-micrometers to micrometers using, for example, a mill, a grinding machine, a ball mill, or a vibrating mill to obtain the fine viral inactivation particles. No particular limitations are imposed on spraying, and either wet or dry process can be used.
    [00039] Then, the finely pulverized viral inactivation particles are dispersed in a solvent such as water, methanol, ethanol, MEK (methyl ethyl ketone), acetone, xylene, or toluene. At this point, other materials such as a binder component, including a silane monomer or an oligomer thereof, and functional materials can be blended into the dispersion. Then a dispersing agent such as a surfactant is added if necessary, and the resulting mixture is dispersed and pulverized using an apparatus such as a glass micro ball mill, a ball mill, a sand mill, a roller mill, a vibrating mill, or a homogenizer, thereby preparing a suspension containing the fine particles of viral inactivation dispersed therein. when the suspension is prepared in the manner described above, the particle diameter of the fine viral inactivation particles is reduced, and these particles are arranged on the surface of the filter member 1 constituting the mask body 10 without excessively wide gaps formed between the particles. The particle density of the fine viral inactivation particles can thereby be increased, and therefore, a high viral inactivation ability can be achieved.
    [00040] The suspension prepared as described above is applied to the surface of the filter member 1 using a method such as a dip method, a spray method, a roller coating method, a rod coating method, a method of spin coating, a gravure printing method, an OFFSET printing method, a screen printing method, or an inkjet printing method. If necessary, the solvent is removed by, for example, heating or drying. Then, the functional groups on the surface of the filter member 1 are chemically attached to the silane monomer via graft polymerization by reheating or graft polymerization by irradiation with infrared rays, ultraviolet rays, an electron beam, or radioactive rays such as y-rays. During graft polymerization, the fine viral inactivation particles are bonded together through silane monomer. By carrying out such a process, the filter member 1 which holds the fine viral inactivation particles having a viral inactivation ability can be obtained.
    [00041] Next, a mask body 10 is formed using the filter member 1. The mask body 10 is pleated, and rubber cords 2 are sewn together to obtain the mask 100 of the first configuration. In this process, the three filter members 1 are stacked and stitched together, and an integrated stacked body is thereby obtained and used as the mask body 10,
    [00042] With the mask 100 described above in the first configuration, several viruses can be inactivated regardless of the genome types and whether or not the viruses have an envelope. Examples of the viruses include rhinovirus, polyvirus, foot-and-mouth disease virus, rotavirus, norovirus, enterovirus, hepatovirus, astrovirus, frog virus, hepatitis E virus, influenza virus type A, B, and C, influenza virus, virus mumps, measles virus, human metapneumovirus, RS virus, Nipah virus, Hendra virus, yellow fever virus, dengue virus, Japanese encephalitis virus, West Nile virus, hepatitis B and C virus, western equine encephalitis virus and eastern, O'nyong-nyong virus, rubella virus, Lassa virus, Junin virus, Machupo virus, Guanarito virus, Sabia virus, Crimean-Congo virus hemorrhagic fever, Mediterranean dengue virus, Tapir virus, virus Sin Nombre, rabies virus, Ebola virus, Marburg virus, Lissa virus, Australian bat, human T-lymphotropic virus, human immunodeficiency virus, human corona virus, corona virus SARS (severe acute respiratory syndrome), parvo human virus, phlegm virus , human papilloma virus, the denovirus, herpes virus, varicella zoster virus, EB virus, cytomegalovirus, smallpox virus, konkeypox virus, cowpox virus, molluscum contagiosum virus, and parapoxvirus.
    [00043] In the mask 100 of the first configuration, viruses can be inactivated even in the presence of, in addition to the virus, lipids and proteins resulting from, for example, the adhesion droplets.
    [00044] In this sense, with mask 100 of the first configuration, the virus adhering to the mask can be inactivated. Therefore, the user can be prevented from viral infection, and the spread of the virus from an infected person can be suppressed. In addition, the occurrence of a secondary infection due to contact with the used mask 100 can be reduced.
    [00045] (Second configuration)
    [00046] In the mask 100 of the second configuration, in addition to the viral inactivation fine particles (in the following may be referred to as the first inorganic fine particles), the second inorganic fine particle used as additional fine particles are retained in the filter members 1. In the second In this configuration, the second inorganic fine particle together with the first inorganic fine particle form inorganic fine particle aggregates in which the inorganic fine particles are arranged di- or three-dimensionally. In other words, in the second configuration, the inorganic particle aggregates containing the first inorganic fine particle and the second inorganic fine particle are held in filter members 1. The structures common to those in the first configuration are by the same reference numbers, and the description will be omitted.
    [00047] The second inorganic fine particles are joined to the filter member 1 through a silane monomer or oligomer thereof and are also joined to each other through the silane monomer or oligomer thereof. Furthermore, in the second configuration, the first inorganic fine particle serving as the viral inactivation fine particles are bonded to the filter member 1 and the second inorganic fine particle through the silane monomer or oligomer thereof and are held in the filter member 1. In the second configuration, the first inorganic fine particles are held in filter member 1 so that they are intertwined with groups of second inorganic fine particles bonded together through the silane monomer or oligomer thereof. Therefore, the first inorganic fine particles are prevented from falling into the filter member 1 not only by chemical bonds but also physically. In the second configuration mask, the fine viral inactivation particles are more effectively prevented from falling out as compared to those in the first configuration mask. Furthermore, the viral inactivation ability can be maintained for a long period.
    [00048] In the second configuration, the groups of the second inorganic fine particles that are joined together through the silane monomer prevent the first inorganic fine particles from falling out of the filter member 1. Furthermore, the first inorganic fine particles cannot form bonds with the second inorganic fine particles and the filter member through the silane monomer.
    [00049] In the mask 100 of the second configuration, the first inorganic fine particles serving as fine particles of viral inactivation are joined to the second inorganic fine particles and the filter member through the silane monomer or oligomer thereof, and consequently, the surfaces of the first inorganic fine particles are exposed, as in the first configuration. Therefore, the probability of contact of the virus adhering to the surface of the mask 100 with the viral inactivation fine particles can be made more than when the viral inactivation fine particles are fixed to the filter member 1 using, for example, a general agglutinator, so that viruses can be effectively inactivated even using a small amount of fine viral inactivation particles.
    [00050] No particular limitation is imposed on second inorganic fine particles according to the second configuration, as long as they can be joined to the silane monomer or oligomer thereof, and a person skilled in the art can select the appropriate second inorganic fine particles. Specifically, non-metal oxides, metal oxides, composite metal oxides, nitrides, carbides, silicates, and mixtures thereof can be used. The second fine inorganic particles can be amorphous or crystalline. Examples of non-metallic oxides include silicon oxide. Examples of metal oxides include magnesium oxide, barium oxide, barium peroxide, aluminum oxide, tin oxide, titanium oxide, zinc oxide, titanium peroxide, zirconium oxide, iron oxide, iron hydroxide, oxide tungsten, bismuth oxide, indium oxide, gibbsite, boehmite, diaspore, antimony oxide, cobalt oxide, niobium oxide, manganese oxide, nickel oxide, cerium oxide, yttrium oxide, and praseodymium oxide. Examples of metal composite oxides include titanium and barium oxide, aluminum and cobalt oxide, lead zirconium oxide, lead niobium oxide, TiO2-WO3, AlO3-SiO2, WO3-ZrO2, WO3-SnO2, CeO2-ZrO2 , In-Sn, Sb-Sn, Sb-Zn, In-Sn-Zn, B2O3-SiO2, P2O5-SiO2, TiO2-SiO2, ZrO2-SiO2, Al2O3-TiO2, Al2O3-ZrO2, Al2O3-CaO, Al2O3-B2O3 , Al2O3-P2O5, Al2O3-CeO2, Al2O3-Fe2O3, TiO2-ZrO2, TiO2-ZrO2-SiO2, TiO2-ZrO2-Al2O3, TiO2-Al2O3-SiO2, and TiO2-CeO2-SiO2. Examples of nitrides include titanium nitride, tantalum nitride, and niobium nitride. Examples of carbides include silicon carbide, titanium carbide, and niobium carbide. Examples of adsorptive silicates include: synthetic zeolites such as zeolite A, zeolite P, zeolite X, and zeolite Y; natural zeolites such as clinoptilolite, sepiolite, and mordenite; filiform silicate compounds such as kaolinite, montmorillonite, tmorillonite, Japanese acid clay and diatomaceous earth; and cyclosilicate compounds such as valostonite and neptunite. Other examples include phosphate compounds such as tricalcium phosphate, calcium phosphate, calcium pyrophosphate, calcium metaphosphate, activated carbon and porous glass.
    [00051] Particularly, when particles having the ability to adsorb proteins are used as the second inorganic fine particles, they can adsorb allergenic proteins such as pollen and mites. In this sense, the combined use of such particles with the fine viral inactivating particles described above having the protein denaturizing effect can provide a mask having not only the viral inactivation ability but also the anti-allergenic performance.
    [00052] A person skilled in the art can appropriately establish the diameter of the second inorganic fine particles, according to, for example, the purpose of use and application of the mask and the diameter of the second inorganic fine particles. In consideration of the binding force to the filter member 1, the diameter of the second inorganic fine particles is preferably 500 nm or less and more preferably 300 nm or less. As described above, one skilled in the art can appropriately establish the particle diameter of the second inorganic fine particles. However, because of the same reason as for the virus inactivating fine particles, the diameter is preferably 1 nm or more.
    [00053] The method of manufacturing the mask 100 of the second configuration having fine particles of viral inactivation maintained therein will be described more specifically below.
    [00054] First, as in the first configuration, at least one is selected from platinum (II) iodide, palladium (II) iodide, copper (i) iodide, silver (I) iodide and copper (I) thiocyanate , and the selected material is sprayed onto particles on the order of micrometers using, for example, a jet mill, a grinding machine, a ball mill, or a vibrating mill to obtain the fine viral inactivation particles. No particular limitations are imposed on spraying, and any of the wet and dry processes can be used.
    [00055] Then, the pulverized viral inactivation fine particles are mixed with the second inorganic fine particles to which the silane monomer has been bound through dehydration condensation, and the mixture is dispersed in a solvent such as water, methanol, ethanol, MEK (methyl ethyl ketone), acetone, xylene, or toluene. In addition to the viral inactivation fine particles and the second inorganic fine particles to which the silane monomer has been bound, other materials such as a binder component and functional materials can be added to the solvent at this point. Then, a dispersing agent such as a surfactant is added if necessary, and the resulting mixture is dispersed and pulverized using an apparatus such as a glass microsphere mill, a ball mill, an earth mill, a roller mill, a vibrating mill, or a homogenizer to prepare a suspension containing the viral inactivation fine particles and the second inorganic fine particles dispersed therein. When the suspension is prepared in the manner described above, the diameters of the viral inactivation fine particles and the second inorganic fine particles are reduced, and the first viral inactivation fine particles and the second inorganic fine particles are arranged on the surface of the filter member 1 constituting the mask body 10 without excessively wide slits formed between the particles. The particle density of the viral inactivation fine particles can thereby be increased, and the groups of the second inorganic fine particles can be more firmly affixed to the surface of the filter member 1 constituting the mask body 10, Therefore, an inactivation ability viral inactivation can be achieved, and the ability of viral inactivation can be maintained for a long period.
    [00056] The chemical bonds between the second inorganic fine particles and the silane monomer can be formed by a usual method. In one example, the silane monomer is added to a dispersion, and the resulting dispersion is heated to reflux to allow the silane monomer to be bonded onto the surfaces of the second inorganic fine particles through a condensation-dehydration reaction to through in addition to form thin films made of silane monomer. In another exemplary method, the silane monomer is added to a dispersion that has been sprayed to reduce particle size, or alternatively, the silane monomer is added to a dispersion of the second inorganic fine particles, and the resulting dispersion is subjected to spray to reduce particle size. Then, the solid and the liquid are separated from each other, and the solid is heated under 100°C to 180°C to allow the silane monomer to be bonded to the surfaces of the second inorganic fine particles through a condensation- dehydration. The resulting particles are pulverized and then re-dispersed.
    [00057] In the methods described above, the amount of silane monomer to be added to the dispersion depends on the proportion of the particle diameter and the material of the second inorganic fine particles. However, when the amount is 3 percent by mass to 30 percent by mass based on the mass of the second inorganic fine particles, the mutual binding force between the second inorganic fine particles and the binding force between the groups of the second inorganic fine particles and the filter member constituting the mask body 10 of the present invention does not cause any practical problem. Even after silane monomer and the like are joined to the first inorganic fine particles, the surfaces of the first inorganic fine particles are sufficiently exposed. Also, an excess of silane monomer that is not involved in bonding may be present.
    [00058] The description of the fabrication method of the mask 100 of the second configuration will be continued. As in the first embodiment, the suspension prepares above is applied to the surface of the filter member 1 using a method such as a dip method, a spray method, a roll coating method, a rod coating method, a spray method. spin coating, a gravure printing method, an OFFSET printing method, a screen printing method, or an inkjet printing method. If necessary, the solvent is removed by heating and drying and the like. Furthermore, the functional groups on the surface of the filter member 1 are chemically bonded through graft polymerization by reheating or graft polymerization by irradiation with infrared rays, ultraviolet rays, an electron beam, or radioactive rays such as Y rays, to the silane monomer bonded to the surfaces of the second inorganic fine particles that coat the surface of filter member 1. At the same time, the silane monomers on the surfaces of the second inorganic fine particles are chemically bonded together to form an oligomer. At the same time, the viral inactivation fine particles are bound to the second inorganic fine particles through the silane monomer. When a binder (another silane monomer) is added, the viral inactivation fines are bonded to the second inorganic fines and mask body 10 via the formed silane monomer or oligomer. By carrying out such a process, the viral inactivating fine particles having a viral inactivating ability are surrounded by the groups of second inorganic fine particles, and the filter member 1 holding the viral inactivating fine particles on the surface thereof is thereby obtained .
    [00059] Then, the mask body 10 is formed using the filter members 1, and the mask body 10 is pleated. Then, rubber cords 2 are sewn into the mask body 10 to obtain the mask 100 of the first configuration. In this process in the second configuration, as in the first configuration, three filter members 1 are stacked and stitched together, and an integrated stacked body is thereby obtained and used as the mask body 10,
    [00060] In the above description, the silane monomer is bound to the second inorganic fine particles in advance, but this mode is not a limitation. The viral inactivation fine particles, the second inorganic fine particles to which no silane monomer has been bound, and the silane monomer can be dispersed in a medium dispersion. A person skilled in the art can properly establish the amount of silane monomer added. As in the description above, the amount added can be, for example, 3 percent by mass to 30 percent by mass based on the mass of the second inorganic fine particles. In the above addition ratio, the mutual binding force between the second inorganic fine particles and the binding force between the groups of the second inorganic fine particles and the filter member constituting the mask body 10 of the present invention does not cause any practical problems. Even after the silane monomer is bound to the second inorganic fine particles, the surfaces of the first inorganic fine particles are sufficiently exposed.
    [00061] (Other settings)
    [00062] The masks 100 of the first and second configurations were described above. However, the present invention is not limited thereto, and other configurations are, of course, possible. For example, the shape of the mask 100 is not limited to the type shown in Fig. 1. As shown in Fig. 3, the mask can be shaped by stamping using a hot press. Furthermore, the invention can be applied to a gauze mask shown in Fig. 4.
    [00063] Stacked Filter 1 members can have different roles. For example, filter members 1 that are located on the inner and outer sides during mask wear and may be subject to antibacterial treatment and deodorization to prevent foul odors and the spread of bacteria. In the first and second configurations, the mask body is composed of a plurality of filter members 1. Of course, the mask body can be composed of a filter member. However, when a plurality of filter members 1 are stacked to constitute a mask body 10, viruses can be more efficiently inactivated compared to when a filter member 1 is used to form a mask body.
    [00064] In another embodiment, a filter member having a different function or configuration than the above-described filter members 1 having the virus inactivating fine particles held therein can be stacked on these filter members 1 to constitute a mask body 10, For example, filter members 1 having the fine viral inactivation particles held therein are disposed on the inner and outer sides when the mask is put on, and a filter member, such as an electret, having high efficiency of dirt collection (hereafter may be referred to as an electret filter member) is disposed between these filter members 1. In other words, this mask body 100 is configured so that the electret filter member and filter members 1 are stacked so as to be sandwiched between the two filter members 1, and the fine viral inactivation particles are kept at least in the filter members disposed on the upper sides. s inner and outer when the mask is worn. With this configuration, even when the filter members have a low unit weight, which can make breathing easier, sufficient dirt collection efficiency can be obtained. Filter members 1 are stacked on the electret filter member so as to be located on the innermost and outermost sides. In this sense, viruses in droplets sprayed from virus carriers and virus floating in the air can be collected and inactivated by the outermost filter member 1, and viruses present in droplets from the user's mouth and nose can be collected and inactivated by the innermost filter member around mouth and nose.
    [00065] When the mask body 10 includes a plurality of stacked filter members 1, it is preferable that at least one of the filter member 1 having the inorganic particles held therein is disposed on the innermost side when the mask is put on. With this setting, viruses present in droplets from the user's mouth and nose can be inactivated, and viral inactivation effects can be provided by the mixture contained in the user's breath. In a conventional mask in which the material having a viral inactivation ability is different from the fine viral inactivation particles of the present configuration, the effect is significantly reduced by the user originating lipids and proteins, when a filter member having such a material held in the even is arranged on the innermost side. However, in the mask of the present invention in which the fine viral inactivation particles kept therein can maintain their inactivation abilities even in the presence of lipids and proteins, when the filter member holding the fine viral inactivation particles is disposed at least on the side more internal, the virus inactivation effect can be enhanced.
    [00066] When the mask body 10 includes a plurality of stacked filter members 1, at least the filter member disposed on the outermost side when the mask is donned can keep the fine particles of viral inactivation therein. With this configuration, virus droplets sprayed from virus carriers and virus floating in the air can be inactivated on the outer side. In this sense, even if the hand comes into contact with the mask surface when the mask is worn or removed, secondary infection is less likely to occur. It is more preferable that the filter members holding the fine viral inactivation particles are disposed at least on the inner and outer sides when the mask is put on, because viral inactivation effects can be provided and also virus droplets and fluctuation of the virus in the air can be inactivated.
    [00067] In the first configuration, the virus inactivating fine particles are maintained on the outer surfaces of the filter members through the silane monomer or its oligomer. However, the fine particles of viral inactivation can be kept in the mask body in a different way. For example, fine viral inactivation particles can be held in filter member 1 by a binder component. No particular limitations are imposed on the contact binder component that has high adhesion to the base material (the material of filter members 1). Examples of usable materials include synthetic resins such as polyester resins, amine resins, epoxy resins, polyurethane resins, acrylic resins, water-soluble resins, vinyl-based resins, fluoro resins, silicone resins, cellulosic resins, phenolic resins, resins xylene, and toluene resins; and natural resins such as castor oil and drying oil for example linseed oil and tung oil.
    [00068] In the first and second configurations, the fine viral inactivation particles are retained on the surfaces of the filter members, but this is not a limitation. The fine particles of viral inactivation can be kept in the mask as a whole. For example, the fine viral inactivation particles can be kept so that they are surrounded by fibers constituting the filter members 1.
    [00069] The present invention will be specifically described below by way of Examples. However, the present invention is not limited to these Examples only.[Examples]
    [00070] (Examination of the viral inactivation ability of fine particles of viral inactivation)
    [00071] Before the effects of the mask of the present invention are examined, the viral inactivation ability of the fine viral inactivation particles formed by any of platinum(II) iodide, palladium(II) iodide, silver(I) iodide, copper (I) iodide, and copper (I) thiocyanate and to be retained in filter member 1 of mask body 10 were examined. The examination was performed using a hemagglutination inhibition (HA) assay commonly used to measure the titer of a virus. An influenza virus (influenza A/Kitakyusyu/159/93(H3N2)) grown in MDCK cells was used as a target virus.
    [00072] More specifically, the two double dilution series of a viral solution was prepared in a 96 pore plate made of plastic. Then 50 μL of 0.5% young blood cell suspension was added to each of the pores. The pores were allowed to rest at 4°C for 1 hour, and then an HA titer was determined. The HA titer determined was 128. Soon after, the fine particles of viral inactivation were diluted to 10% by mass with phosphate-buffered saline. 450 µL of the viral solution was added to 450 µL of the diluted solution, and the resulting solution was allowed to react at room temperature for 10 minutes under agitation using a micro-tube rotator. The powder was precipitated by centrifugation, and 150 μL of the supernatant was collected and used as a sample. Double dilution series of the obtained sample solution was prepared. Then, an equal amount of 0.5% suspension of young blood cells was added. The resulting solutions were allowed to stand at 4°C for 60 minutes, and an HA titer was determined. The results are shown in Table 1.

    [00073] As can be seen from the above results, the fine viral inactivation particles formed from any one of platinum(II) iodide, palladium(II) iodide, silver(I) iodide, copper(I) iodide and Copper(I) thiocyanate have been found to have the ability to inactivate influenza virus with an HA titer of 2 to 64.
    [00074] (Production of filter 1 members having the inactivation effect of various viruses)
    [00075] Example 1:
    [00076] A commercially available powder of copper(I) iodide (product of Wako Pure Chemical Industries, Ltd., Wako 1st category) was used as viral inactivating fine particles having a viral inactivating ability and was sprayed into the average diameter of 170 nm particle using a dry spray, Nano Jetmizer (product of Aishin Nano Technologies CO., Ltd.). The pulverized fine copper (I) iodide particles were added to the ethanol in an amount of 2.0 percent by weight, and tetramethoxy silane (KBM-04, product of Shin-Etsu Chemical Co., Ltd.) was also added. in an amount of 0.4 percent by mass. The mixture was predispersed using a homogenizer for 5 minutes to prepare a solution. The mean particle diameter as used herein is a volume mean particle diameter.
    [00077] In addition, an artificial silk nonwoven (product of SHINWA Corp.) of 20 g/m2 was immersed in the prepared solution. Any excess solution was removed, and the non-woven fabric was dried under 120°C for 10 minutes to obtain a filter member 1 having a viral inactivating effect.
    [00078] Example 2:
    [00079] 100.0 g of a commercially available powder of copper(I) thiocyanate (product of Wako Pure Chemical Industries, Ltd., chemical use) used as viral inactivation fine particles (first inorganic fine particle) was pre-dispersed in 900.0g of ethanol and then pulverized and dispersed using a glass microsphere mill to obtain a solution having an average particle diameter of 104 nm.
    [00080] Next, methacryloxypropyltrimethoxy silane (KBM-503, product of Shin-Etsu Chemical Co., Ltd.), a silane monomer having an unsaturated bonding moiety, was subjected to condensation-dehydration by a usual method to covalently join silane to the surfaces of zirconium oxide particles (PCS, product of Nippon Denko Co., Ltd.), and the resulting particles were used as second inorganic fine particles. 100.0 g of the second inorganic fine particles were pre-dispersed in the ethanol and were pulverized and dispersed using a glass microsphere mill to obtain a solution having an average particle diameter of 15.1 nm. The mean particle diameter as used herein is a volume mean particle diameter.
    [00081] The above two types of solutions were mixed at a mixing ratio of 40 percent by mass copper thiocyanate dispersion and 60 percent by mass zirconium oxide particle dispersion, and ethanol was added to the mixture to that the concentration of the solid content is adjusted to 3 percent by mass (hereinafter the resulting solution is referred to as a mixed solution).
    [00082] Then, tetramethoxy silane (KBM-04, product of Shin-Etsu Chemical Co., Ltd.) was added to the mixed solution in an amount of 0.3 percent by mass, and the non-woven artificial silk ( product of KURARAYKURAFLEX Co., Ltd.) of 18 g/m2 was dipped with the resulting mixture and then dried to obtain a filter member 1 having a viral inactivating effect.
    [00083] Example 3:
    [00084] 40.0 g of a commercially available powder of copper(I) iodide (product of Wako Pure Chemical Industries, Ltd., Wako 1st grade) used as viral inactivation fine particles (first inorganic fine particles) having an ability of viral inactivation and 60.0 g of zirconium oxide particles (product of Nippon Denko Co., Ltd.) used as the second inorganic fine particles were pre-dispersed in 900.0 g of ethanol. These particles were pulverized and dispersed using a glass microsphere mill to obtain a solution containing copper(I) iodide fine particles having an average particle diameter of 205 nm and zirconium oxide fine particles having an average particle diameter of 37 nm. Ethanol was added to the obtained solution so that the solid content concentration was adjusted to 1 percent by mass. The mean particle diameter as used herein is a volume mean particle diameter.
    [00085] In addition, tetramethoxy silane (KBM-04, product of Shin-Etsu Chemical Co., Ltd.) was added to the above solution in an amount of 0.3 percent by mass, and the particles were dispersed using a homogenizer . A non-woven artificial silk (product of KURARAYKURAFLEX Co., Ltd.) of 18 g/m2 was impregnated with a resulting solution and dried to obtain a filter member 1 having a viral inactivating effect.
    [00086] Example 4:
    [00087] A commercially available silver (I) iodide powder (product of Wako Pure Chemical Industries, Ltd., chemical use) was used as viral inactivating fine particles (first inorganic fine particles) having a viral inactivating ability. Methacryloxypropyltrimethoxy silane (KBM-503, product of Shin-Etsu Chemical Co., Ltd.), a monomer having an unsaturated bonding moiety, was subjected to condensation-dehydration by a usual method to covalently bond the silane to the surfaces of the oxide particles. of zirconium (product of Nippon Denko Co., Ltd.), and the resulting particles were used as second inorganic fine particles. 40.0 g of the silver (I) iodide powder and 60.0 g of the second inorganic fine particles were pre-dispersed in 900.0 g of the methanol, and these particles were pulverized and dispersed using a glass microsphere mill to to obtain a paste containing fine particles of silver (I) iodide having an average particle diameter of 124.8 nm and fine particles of zirconium oxide having an average particle diameter of 15.1 nm. Ethanol was added to the obtained solution so that the solid content concentration was adjusted to 3 percent by mass. The mean particle diameter as used herein is a volume mean particle diameter.
    [00088] Next, tetramethoxy silane was added to the solution in an amount of 0.3 percent by weight, and a non-woven artificial silk (product of KURARAYKURAFLEX Co., Ltd.) of 18 g/m2 was dipped with the resulting solution and dried to obtain a filter member 1 having a viral inactivating effect.
    [00089] Example 5:
    [00090] A commercially available powder of copper(I) iodide (product of Wako Pure Chemical Industries, Ltd., Wako 1st grade) was used as viral inactivation fine particles (first inorganic fine particles). Methacryloxypropyltrimethoxy silane (KBM-503, product of Shin-Etsu Chemical Co., Ltd.), a silane monomer having an unsaturated bonding moiety, was subjected to condensation-dehydration by a usual method to covalently bond the silane to the surfaces of the particles. zirconium oxide (PCS, product of Nippon Denko Co., Ltd.), and the resulting particles were used as second inorganic fine particles. 40.0 g of the copper(I) iodide powder and 60.0 g of the second inorganic fine particles were pre-dispersed in 900.0 g of ethanol, and these particles were pulverized and dispersed using a glass microsphere mill to to obtain a solution containing fine particles of copper(I) iodide having an average particle diameter of 60 nm and fine particles of zirconium oxide covered with metal acryloxypropyltrimethoxy silane having an average particle diameter of 37 nm. Ethanol was added to the obtained solution so that the solid content concentration was adjusted to 1 percent by mass. The mean particle diameter as used herein is a volume mean particle diameter.
    [00091] Next, a non-woven artificial silk (product of KURARAYKURAFLEX Co., Ltd.) of 18 g/m2 was dipped with the resulting solution and dried to obtain a filter member 1 having a viral inactivating effect.
    [00092] Example 6:
    [00093] A filter member 1 having a viral inactivating effect was obtained under the same conditions as in Example 5 except that tetramethoxy silane (KBM-04, product of Shin-Etsu Chemical Co., Ltd.) was added in one amount of 0.3 percent by mass the solution used in Example 5.
    [00094] Comparative Example 1:
    [00095] A filter member of Comparative Example 1 was obtained under the same conditions as in Example 6 except that the fine viral inactivation particles used in Example 6 were not added.
    [00096] Comparative Example 2:
    [00097] Only a non-woven artificial silk (product of KURARAYKURAFLEX Co., Ltd.) of 18 g/m2 was used as a filter member of Comparative Example 2.
    [00098] (Assessment of filter 1 members having viral inactivation effect on various viruses)
    [00099] In measuring the viral inactivation ability of filter limbs, four types of viruses including influenza virus A/yamagata/1/08(H1N1), A/kitakyushu/159/93(H3N2), and B/Bangkok/163 /90, and feline calicivirus strain F9 were used as target viruses. A sample of the non-woven sheet (5 cm x 5 cm) of one of Examples 1, 3, 5, and 6 and Comparative Examples 1 and 2 was placed onto three untreated non-woven sheets, and the sheets were held with tweezers. . 250 μL of an undiluted virus solution was placed in commercially available solution administration and nasal-oral administration apparatus ("shutto AAN vaporizer", product of Keytron, a device that can spray the liquid as droplets having a size corresponding to the oral-nasal droplet size), and the total amount of viral solution was sprayed onto the non-tissue at a distance of 10 cm. The sample sprayed with the viral solution was placed in sterile plastic petri dishes. After sensitization for 60 minutes, 1 ml of a broth solution was added to drive the virus away. Then a reaction sample was diluted with a 10-2 to 10-5 MEM diluent solution (ten serial dilutions), and 100 µL of the diluted sample solutions were inoculated into MDCK cells. After virus adsorption for 90 minutes, 0.7% agar medium was placed on it, and the virus was cultured under 34°C in 5% CO2 for 48 hours in the incubator. After formalin fixation and methylene blue staining were performed, the number of formed platelets was contained to calculate the virus infectivity titer (PFU/0.1 mL, Log10) (PFU: platelet-forming units), and the titer of calculated infectivity of the virus was compared with that of a control.(Control)
    [000100] A 5 cm square plastic film was used as a virus control instead of the non-woven sheet test.
    (Assessment of the viral inactivation effect in the presence of protein)
    [000101] In measuring the viral inactivation ability of the filter limbs, BSA (bovine serum albumin) was added in the amount of 0.5 by center by mass, which was an estimated amount of proteins contained in saliva, to an undiluted solution from an influenza A virus /kitakyushu/159/93(H3N2) and from an undiluted solution of a feline calicivirus strain F9 that were used as the target virus. A non-woven sheet sample (5 cm x 5 cm) was placed over three untreated non-woven sheets, and the sheets were held in place with tweezers. 250 μL of one of the undiluted virus solutions was placed in commercially available solution administration and nasal-oral administration devices ("AAN shutto vaporizer," Keytron's product, a device that can spray the liquid as droplets having a corresponding size to the size of the oral-nasal droplets), and the total amount of viral solution was sprayed onto the non-tissue at a distance of 10 cm. The sample sprayed with the viral solution was placed in sterile plastic petri dishes. After sensitization for 60 minutes, 1 ml of a broth solution was added to drive the virus away. Then, the reaction was diluted with a 10-2 to 10-5 MEM diluent solution (Ten serial dilutions), and 100 µL of diluted sample solutions were inoculated into MDCK cells. After virus adsorption for 90 minutes, 0.7% agar medium was placed on it, and the virus was cultured under 34°C in 5% CO2 for 48 hours in an incubator. After formalin fixation and methylene blue staining were performed, the number of platelets formed was contained to calculate the virus infectivity titer (PFU/0.1 mL, Log10) (PFU: platelet-forming units), and the titer of calculated infectivity of the virus was compared with that of a control.(Control)
    [000102] A 5 cm square plastic film was used as a virus control rather than the non-woven sheet test.[Table 3]

    [000103] As can be seen from the above results, the inactivating effect of type A and type B influenza viruses was found in Examples 1, 3, 5, and 6. Particularly in Examples 1, 3, and 5, the The observed effect was higher, ie, the proportion of inactivation after 60 minutes was 99.9999% or greater. In Example 6, a small amount of H3N2 virus remained non-inactivated. However, the proportion of inactivation was higher (99.9996%). Even in the presence of the protein, similar results of 99.9999% or greater were obtained except for Example 2. Even in Example 2, the effect was as high as 99.99%. The mask of the present invention configured to include filter members having a viral inactivation ability can inactivate viruses as they adhere to the mask in approximately 1 hour, which varies depending on the amount of the fine viral inactivation particles and the like. In this sense, the mask provided is not a single-use mask and can be used for a long period.
    [000104] Reference Signal List 100: mask10: mask body1: filter member 2: rubber rope3: wire-shaped bands4: folds
    权利要求:
    Claims (6)
    [0001]
    1. "MASK" capable of inactivating a virus adhering to it, characterized by comprising a mask body provided with a limb worn when the mask is worn, and fine particles of viral inactivation having an ability to inactivate viruses and retain them in the body of the mask, the fine viral inactivation particles being particles of at least one of the selected groups consisting of platinum (II) iodide, palladium (II) iodide, silver (I) iodide, copper (I) iodide, and copper(I) thiocyanate, wherein the fine viral inactivation particles are fixed to the mask body at least through a silane monomer and/or a silane monomer polymerization product.
    [0002]
    2. "MASK", capable of inactivating a virus that adheres to it, the mask characterized by comprising a mask body provided with a limb used when the mask is used, and fine particles of viral inactivation with the ability to inactivate virus and retain they are not maintained by the body of the mask, the fine virus inactivating particles being particles of at least one selected from the group consisting of platinum(II) iodide, palladium(II) iodide, silver(I) iodide, copper iodide (I) and copper thiocyanate (I) where the fine viral inactivation particles are retained in the mask body through groups of other fine inorganic particles that are attached to the mask body through chemical bonds with a silane monomer and/or a polymerization product of the silane monomer.
    [0003]
    3. "MASK" according to any one of the preceding claims, characterized in that the mask body includes a plurality of breathable filter members stacked in a thickness direction of the mask body, and the fine viral inactivation particles are maintained by at least one of the plurality of filter members constituting the mask body.
    [0004]
    4. "MASK", according to claim 3, characterized in that the fine particles of viral inactivation are maintained by at least one filter member which is located on the innermost side when the mask is put on.
    [0005]
    5. "MASK" according to any one of claims 3 or 4, characterized in that the fine particles of viral inactivation are maintained by at least one filter member which is located on the outermost side when the mask is put on.
    [0006]
    6. "MASK", according to any one of the preceding claims, characterized in that the average diameter of the fine particles of viral inactivation is 1 nm or more and less than 500 nm.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112012006914B1|2021-06-01|MASK
    RU2550922C2|2015-05-20|Virus inactivating cloth
    Zhou et al.2020|Progress and perspective of antiviral protective material
    US20100040655A1|2010-02-18|Anti-viral Formulations Nanomaterials And Nanoparticles
    BRPI0917773B1|2019-02-05|antiviral fibrous structure
    TWI729229B|2021-06-01|Face mask
    JP5406245B2|2014-02-05|Wipe sheet
    Goswami et al.2021|Facile development of graphene-based air filters mounted on a 3D printed mask for COVID-19
    JP5912273B2|2016-04-27|Antiviral agent and method for producing the same
    JP2013067577A|2013-04-18|Antiviral agent and member using the same
    Jazie et al.2021|A review on recent trends of antiviral nanoparticles and airborne filters: special insight on COVID-19 virus
    WO2021229444A1|2021-11-18|Novel and improved biodegradable face mask with inherent virucide, hydrophobic and hydrophillic properties with adjustable ear loops
    Moore2021|Processes and Methods for Creating New Types of Personal Protective Gears
    同族专利:
    公开号 | 公开日
    RU2012115650A|2013-11-10|
    BR112012006914A2|2020-10-06|
    KR101772716B1|2017-08-29|
    CN102548619A|2012-07-04|
    IN2012DN02357A|2015-08-21|
    US10744351B2|2020-08-18|
    RU2549065C2|2015-04-20|
    EP2484409A1|2012-08-08|
    KR20120096477A|2012-08-30|
    AU2010302079B2|2015-04-02|
    EP2484409B1|2018-02-14|
    JPWO2011040035A1|2013-02-21|
    US20120192876A1|2012-08-02|
    WO2011040035A1|2011-04-07|
    JP5291198B2|2013-09-18|
    EP2484409A4|2016-04-27|
    AU2010302079A1|2012-04-12|
    CA2776031A1|2011-04-07|
    CA2776031C|2018-09-18|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US6281515B1|1998-12-07|2001-08-28|Meridian Research And Development|Lightweight radiation protective garments|
    US8192765B2|2000-06-21|2012-06-05|Icet, Inc.|Material compositions for microbial and chemical protection|
    JP3633883B2|2001-05-28|2005-03-30|松下エコシステムズ株式会社|Antiviral mask|
    JP3642340B2|2003-03-28|2005-04-27|ダイキン工業株式会社|Hazardous substance removing method, air purifying filter, wiping sheet and other harmful substance removing material used therefor, and storage method thereof|
    JP4004987B2|2003-04-15|2007-11-07|トーコー衛材株式会社|Sanitary or medical anti-influenza virus mask|
    JP2004323430A|2003-04-25|2004-11-18|Toyo Ink Mfg Co Ltd|Antibacterial and antiviral material and application thereof|
    JP2005028230A|2003-07-09|2005-02-03|Arupiko Kk|Sterilizing filter and mask using the same|
    US20070169278A1|2004-03-01|2007-07-26|Japan Exlan Co., Ltd.|Anti- viral fiber, process for producing the fiber, and textile product comprising the fiber|
    JP4594182B2|2005-07-20|2010-12-08|大王製紙株式会社|3D mask|
    US20070175477A1|2005-12-23|2007-08-02|Baggett Richard W|Personal protection, procedural and surgical mask|
    AU2006335491B2|2006-01-13|2011-01-27|Nbc Meshtec Inc|Composite material having antifouling property|
    US20070292486A1|2006-06-15|2007-12-20|The Penn State Research Foundation|Novel polymer-nano/microparticle composites|
    JP2008188082A|2007-02-01|2008-08-21|Nisshinbo Ind Inc|Mask|
    EP1953286A1|2007-02-01|2008-08-06|Nisshinbo Industries, Inc.|Fabric and mask|
    US7520923B2|2007-03-22|2009-04-21|Mvp Textiles & Apparel, Inc.|Antimicrobial filtration article|
    US20080295843A1|2007-06-01|2008-12-04|Haas Marci B|Self sanitizing face masks and method of manufacture|
    KR101074359B1|2008-01-03|2011-10-17|코오롱패션머티리얼 |Filter media of facial mask|
    CN101939382B|2008-02-12|2012-11-28|帝人高科技产品株式会社|Flame-retardant resin composition, flame-retardant fiber, flame-retardant cloth, and heat-resistant protective clothing|
    JP3151082U|2008-10-07|2009-06-11|小川　倉一|Multifunctional mask|
    CA2746980C|2008-12-26|2016-10-11|Nbc Meshtec, Inc.|Anti-viral composition containing univalent copper compound|
    AU2010302092B2|2009-10-02|2014-11-06|Nbc Meshtec, Inc.|Virus inactivation sheet|AU2010302092B2|2009-10-02|2014-11-06|Nbc Meshtec, Inc.|Virus inactivation sheet|
    US9155310B2|2011-05-24|2015-10-13|Agienic, Inc.|Antimicrobial compositions for use in products for petroleum extraction, personal care, wound care and other applications|
    JP6002757B2|2011-05-24|2016-10-05|アジエニック，インコーポレイテッド|Composition and method of antibacterial metal nanoparticles|
    CN104125849A|2012-03-07|2014-10-29|东亚合成株式会社|Deodorizing mask|
    WO2014122790A1|2013-02-08|2014-08-14|株式会社ビー・エヌ|Mask|
    JP6290688B2|2014-03-31|2018-03-07|株式会社Ｎｂｃメッシュテック|Bactericidal and antiviral components|
    KR20170095209A|2014-11-12|2017-08-22|필리스 쿤|Cidal metal or cidal metal alloy mask|
    US9420835B2|2014-12-08|2016-08-23|David Jorge|Mouth mesh|
    WO2016099417A1|2014-12-16|2016-06-23|Kaya Cengiz|A modular antimicrobial and antiviral face mask and a manufacturing method against epidemics|
    US20160262466A1|2015-03-09|2016-09-15|Garry Tsaur|Air permeable mask|
    CN105214237A|2015-11-13|2016-01-06|朱忠良|A kind of breathing mask of applicable high pollution weather|
    CN105214236A|2015-11-13|2016-01-06|朱忠良|A kind of breathing mask of applicable high pollution weather|
    USD782029S1|2015-12-18|2017-03-21|Phyllis Kuhn|Mask|
    US10617894B2|2016-04-05|2020-04-14|Innonix Technologies, Incorporated|Compositions for reducing inhalation of toxic air pollution components|
    KR101867157B1|2016-06-13|2018-06-12|최춘해|Dust mask|
    CN109328048B|2016-06-17|2021-09-07|花王株式会社|Steam heating appliance and method of using the same|
    CN109310166A|2016-06-30|2019-02-05|株式会社科莱尔|Mask, breathing load type mask and gauze mask box|
    USD872256S1|2016-08-17|2020-01-07|Masgick, Inc.|Strapless collapsible respiratory mask|
    US20190231004A1|2016-10-17|2019-08-01|Nbc Meshtec Inc.|Mask|
    USD849928S1|2017-05-15|2019-05-28|Jonathan Grover|Facemask|
    USD822195S1|2017-05-30|2018-07-03|Ascend Eagle Incorporated|Medical mask|
    USD854144S1|2017-09-05|2019-07-16|Prestige Ameritech, Ltd.|Ear loop mask|
    US11124901B2|2017-11-27|2021-09-21|First Step Holdings, Llc|Composite fabric, method for forming composite fabric, and use of a composite matter fabric|
    WO2021216608A1|2020-04-20|2021-10-28|First Step Holdings, Llc|Personal protective equipment|
    RU187423U1|2018-02-27|2019-03-05|Александр Андреевич Максимов|Half mask for respiratory protection and / or treatment|
    KR102330342B1|2020-03-02|2021-11-23|경희대학교 산학협력단|Infectious respiratory virus blocking composition and uses thereof|
    DE102020115795A1|2020-03-27|2021-09-30|S. Schweikardt Moden GmbH|Face mask and method of making a face mask|
    RU202267U1|2020-04-03|2021-02-09|Зинаида Николаевна Кудрина|Protective mask|
    TWI722901B|2020-05-21|2021-03-21|豪紳纖維科技股份有限公司|Antibacterial cloth mask and manufacturing method thereof|
    KR102144869B1|2020-06-05|2020-08-14|주식회사 에프앤지아이|Method of Preparing Reusable Functional Mask Having Antibacterial, deodorizing, Anion and Far Infrared Ray Emission Effects|
    WO2021255629A1|2020-06-17|2021-12-23|Silk Medical S.R.L.|Medical device for the protection of the respiratory tract|
    RU2740137C1|2020-06-23|2021-01-11|Владимир Викторович Михайлов|Protective mask |
    KR102346603B1|2020-08-27|2021-12-31|안승성|Mask and the manufacturing method thereof using the moisture containing cloth|
    RU204183U9|2020-09-03|2021-05-17|Общество с ограниченной ответственностью "А Групп"|RESPIRATOR MEDICAL|
    KR102256725B1|2020-11-04|2021-05-26|이정안|Mask with sterilizable filter|
    US11083231B1|2020-12-08|2021-08-10|Randall J Lewis|Sanitizing face mask|
    法律状态:
    2020-10-13| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2021-04-13| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2021-06-01| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/09/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
    优先权:
    申请号 | 申请日 | 专利标题
    JP2009-228884|2009-09-30|
    JP2009228884|2009-09-30|
    PCT/JP2010/005894|WO2011040035A1|2009-09-30|2010-09-30|Mask|
    [返回顶部]